我要投票 德维喜DOVC在其他行业中的票数:584
· 外 推 电 报 ·
2026-01-10 22:37:22 星期六

【德维喜DOVC是哪个国家的品牌?】

德维喜DOVC是什么牌子?「德维喜DOVC」是 东北制药集团股份有限公司 旗下著名品牌。该品牌发源于辽宁省沈阳市,由创始人魏海军在1993-06-10期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力德维喜DOVC品牌出海!将品牌入驻外推网,定制德维喜DOVC品牌推广信息,可以显著提高德维喜DOVC产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

创始于1993年,知名维生素品牌,覆盖医药研发、制造、分销全产业链条,以化学原料药为主的大型综合性制药企业


东北制药集团股份有限公司(简称“东北制药”,股票代码:000597),是辽宁方大集团实业有限公司(简称“方大集团”)旗下上市公司。公司前身为东北制药总厂,始建于1946年,曾援建全国19省市52家医药企业,向外输送干部1300多人。

目前,东北制药拥有化学原料药、化学制剂、医药商业、医药工程、生物医药等主要业务板块,覆盖医药研发、制造、分销全产业链条,员工队伍9300余人,总资产120亿元。公司主要生产维生素系列药品、抗感染系统用药、妇产科系统用药、消化系统用药、泌尿系统用药、抗病毒系列用药、心脑血管系列用药、镇痛镇咳系列用药、生物诊断系列、大健康领域系列等十大系列精品,400多种化学原料药、医药中间体和制剂产品,主导产品远销100多个国家和地区。

公司拥有强大的产品制造体系。制剂生产基地占地18万平方米,拥有生产线30余条,年产能100亿片(支、丸、粒、枚、瓶)。原料药生产基地占地91万平方米,是国家大宗原料药和医药中间体智能制造示范工厂,主要产品包括维生素C及系列、左旋肉碱系列、磷霉素系列、吡拉西坦、卡前列甲酯、金刚烷胺、硫糖铝、黄连素、氯霉素等,并向下游东北制药制剂产业链延伸,形成难以复制的综合竞争优势。

东北制药不仅是中国重要的药品生产与出口基地,还设有药物研究院、工程设计公司、装备制造安装公司、国际贸易公司、计量检测公司、危化品运输公司等各独立业务公司。

东北制药医药商业业务网络覆盖辽宁全部地级市县,并向东北三省延伸,东北大药房拥有百余家连锁店,医药电商业务实现线上线下一体化,商业模式创新持续推进。


英文翻译:Founded in 1993, it is a well-known vitamin brand, covering the whole industrial chain of pharmaceutical research and development, manufacturing and distribution. Northeast Pharmaceutical Group Co., Ltd., a large comprehensive pharmaceutical enterprise mainly engaged in chemical APIs (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597), is a listed company under Liaoning Fangda Group Industry Co., Ltd. (hereinafter referred to as "Fangda group"). The company, formerly known as the Northeast Pharmaceutical General Factory, was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has sent more than 1300 cadres. At present, Northeast Pharmaceutical has major business sectors such as chemical APIs, chemicals, pharmaceutical commerce, pharmaceutical engineering, biomedicine, covering the whole industrial chain of pharmaceutical research and development, manufacturing, distribution, with more than 9300 employees and a total asset of 12 billion yuan. The company mainly produces ten series of high-quality products, including vitamin series, anti infection system medicine, gynecology and obstetrics system medicine, digestive system medicine, urinary system medicine, anti-virus series medicine, cardiovascular and cerebrovascular series medicine, analgesia and antitussive series medicine, biological diagnosis series, large health field series, more than 400 kinds of chemical APIs, pharmaceutical intermediates and preparation products, leading products It is exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of 180000 square meters, with more than 30 production lines and an annual production capacity of 10 billion tablets (pills, granules, tablets, bottles). The API production base covers an area of 910000 square meters. It is a national bulk API and pharmaceutical intermediate intelligent manufacturing demonstration factory. Its main products include vitamin C and series, L-carnitine series, fosfomycin series, piracetam, carboprost methyl ester, amantadine, sucralfate, berberine, chloramphenicol, etc. and it extends to the downstream Northeast Pharmaceutical industry chain, forming a hard to replicate Comprehensive competitive advantage. Northeast Pharmaceutical is not only an important pharmaceutical production and export base in China, but also has independent business companies such as pharmaceutical research institute, engineering design company, equipment manufacturing and installation company, international trade company, measurement and testing company, dangerous chemicals transportation company, etc. The Northeast Pharmaceutical business network covers all prefecture level cities and counties in Liaoning, and extends to three provinces in Northeast China. The Northeast pharmacy has more than 100 chain stores. The online and offline integration of pharmaceutical e-commerce business is realized, and the innovation of business model is continuously promoted.

本文链接: https://www.waitui.com/brand/aa403ad85.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

马斯克透露特斯拉有大约15万员工,持H-1B签证者不到3000人

一位网友分享美国科技公司雇佣持H-1B签证员工数量的图表,显示特斯拉(445.01, 9.21, 2.11%)雇佣着2908名此类员工,并敦促马斯克在特斯拉裁减持H-1B签证员工的数量。马斯克回应称:“我们这样做绝不是为了省钱。而是为了聘请那些具备专业技能的杰出人才加入我们的团队,而且是以高成本。此外,我们有15万名员工,所以这只是百分之几。”(新浪财经)

38分钟前

雷军:特斯拉确实强,但并非不可战胜

36氪获悉,1月10日,雷军发文称:“看了易车网销量排行榜:特斯拉确实强,但并非不可战胜!我自豪的是,SU7是迄今为止唯一击败Model 3 的同档纯电轿车!出色的产品力和品质,才会有这样的销量。小米YU7,上市仅6个月时间,销量和Model Y 有差距。我相信,假以时日,YU7 也能一较高下!”

38分钟前

外资开年频频加仓中国资产

据上证报,2026年伊始,外资机构对中国资产的配置热情持续升温。记者在港交所披露易检索发现,自2026年1月1日以来,摩根大通在港股密集增持宁德时代、赣锋锂业、信达生物等H股公司,涵盖新能源、生物医药、通信服务等多个领域。“这种现象反映出国际资本对中国经济企稳回升的预期增强,以及港股估值洼地的吸引力凸显,预计2026年内外资机构频频增持的趋势将持续。”一位投行人士对记者表示。此外,2026年以来,景顺中国科技ETF、锐联中国科技创新ETF等多只在美国上市的中国科技类ETF持续吸引资金流入。多家外资巨头认为,中国科技产业长期成长逻辑稳固,中国科技股行情有望在2026年延续。

38分钟前

我国科学家创出全新计算架构提升算力

“傅里叶变换”是频率的“翻译器”,可将声音、图像等复杂信号转换为频率语言,是科学和工程领域一种基础且应用广泛的计算方式。北京大学研究团队创出一种全新的多物理域融合计算架构,可利用后摩尔新器件支持傅里叶变换,使算力提升近4倍,为具身智能、边缘感知、类脑计算、通信系统等领域开辟新的可能。该成果9日发表于《自然-电子学》。(新华社)

38分钟前

美国联邦通信委员会批准SpaceX再部署7500颗星链卫星

当地时间1月9日,美国联邦通信委员会(FCC)向SpaceX授予重大授权。根据该授权,SpaceX获准建造、部署并运营额外7,500颗第二代星链卫星,使全球卫星总数达到15,000颗。(界面新闻)

38分钟前

本页详细列出关于德维喜DOVC的品牌信息,含品牌所属公司介绍,德维喜DOVC所处行业的品牌地位及优势。
咨询